Aducanumab: First Approval

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering

(2021) Jeffrey Cummings et al.   Alzheimers Research & Therapy

Alzheimer’s disease: targeting the glutamatergic system

(2020) Myra E. Conway   BIOGERONTOLOGY

Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease

(2020) Samantha Budd Haeberlein et al.   Alzheimers & Dementia

Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer’s Disease

(2020) Joakim Bastrup et al.   JOURNAL OF ALZHEIMERS DISEASE

Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β

(2018) Joseph W. Arndt et al.   Scientific Reports

Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice

(2016) Ksenia V. Kastanenka et al.   JOURNAL OF NEUROSCIENCE

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Immunotherapeutic Approaches for Alzheimer’s Disease

(2015) Thomas Wisniewski et al.   NEURON

Immunotherapy for Alzheimer's disease

(2014) Thomas Wisniewski et al.   BIOCHEMICAL PHARMACOLOGY

Molecular characterization and preclinical efficacy

(2011) Robert Dunstan et al.   Alzheimers & Dementia